Healthcare company Phosplatin Therapeutics has licensed new anti-cancer compounds that could change the face of chemotherapy treatment.

Using a combination of phosphate and platinum compounds, Professor Rathindra Bose of Ohio University was able to activate specific genes to kill cancer cells without damaging DNA in the nuclei.

Additionally, the compounds were found to overcome the resistance of some patients to platinum chemotherapies.

"Scientifically speaking, this is a paradigm shift for designing platinum cancer therapeutics by targeting multiple pathways to control growth, inhibit spreading and specifically kill cancer cells without binding DNA," said Professor Bose.

Phosplatin Therapeutics has now initiated quarterly payments totalling $600,000 (£370,000) to Ohio University to fund its continuing development of the compounds, with research now to focus on how phosplatins work.

Professor Bose will also now serve as a scientific advisor to Phosplatin Therapeutics.

Recently, Boston Scientific Corporation announced that it has completed patient enrolment for a clinical trial to evaluate its fourth-generation Synergy coronary stent, which incorporates a platinum chromium alloy to promote faster vessel healing.

Source:


New York company to develop Ohio University cancer drug discovery (01/02/11)

© Adfero Ltd